Hemopressin as a breakthrough for the cannabinoid field

Area of Science:

• Pharmacology
• Neuroscience
• Biochemistry

Background:

• Hemopressin, a hemoglobin-derived peptide, was the first identified ligand for the type 1 cannabinoid receptor (CB1).
• Extended hemopressin forms and related peptides exhibit diverse activities at CB1 and CB2 receptors, including agonistic and allosteric effects.
• Recent research indicates potential activation of intracellular mitochondrial cannabinoid receptors by hemopressin-related peptides.

Purpose of the Study:

• To review the molecular and behavioral pharmacology of hemopressins.
• To summarize the unique mechanisms of hemopressin generation and binding to cannabinoid receptors.
• To explore the potential of hemopressins in expanding the endocannabinoid system's signaling repertoire and pharmaceutical applications.

Main Methods:

• Literature review of molecular and behavioral pharmacology studies.
• Analysis of studies on hemopressin generation and receptor binding.
• Evaluation of research on hemopressin's physiological roles and therapeutic potential.

Main Results:

• Hemopressins exhibit location-specific and biased pharmacological actions at cannabinoid receptors.
• These peptides are involved in antinociception, anti-inflammation, appetite regulation, learning, and memory.
• The shortest active fragment, NFKF, demonstrates neuroprotective effects in seizure and autoimmune models.
• Self-assembled hemopressin nanofibrils show pH-sensitive properties and potential for targeted drug delivery in inflammation and cancer.

Conclusions:

• Hemopressins and their analogs possess multifaceted pharmacological profiles, engaging both cannabinoid and non-cannabinoid systems.
• Their ability to modulate the endocannabinoid system and their self-assembly properties present novel therapeutic opportunities.
• Hemopressin-based formulations could enhance anti-inflammatory and anti-cancer treatments.